WALTHAM, Mass., September 22, 2021 (GLOBE NEWSWIRE) – Scipher Medicine, a precision immunology company connecting patients with their most effective therapies, today announced the appointment of John Strumbos, Ph.D., MBA , as Chief Financial Officer. John will be instrumental in guiding Scipher’s financing and capital strategy as the company continues on its rapid growth path.
“We are delighted to welcome John to the Scipher team,” said Alif Saleh, CEO of Scipher Medicine. “John’s background in banking, investment and life science startups uniquely positions him to lead our fundraising strategy from the private and public capital markets. “
“I am delighted to join this fantastic team,” said John. “In oncology, we have already begun to see the transformational promise of precision medicine for patients and the accompanying growth in shareholder value. What drew me to Scipher was to take the same model but apply it to an even greater unmet need in autoimmune diseases, which is the main driver of specialty drug spending in America. “, he added.
John brings over 20 years of capital markets, finance and strategy experience to the life sciences industry. Prior to joining Scipher, he was Vice President of Finance and Strategy at Immunovant, where he led several private and public capital raises totaling $ 560 million in total gross proceeds. Prior to that, John held various life sciences investment positions at Weiss Multi-Strategy Advisors, Buysydr and Citadel. While working for Goldman Sachs and Morgan Stanley, John advised life science companies on capital markets transactions totaling $ 2 billion in gross proceeds and mergers and acquisitions totaling $ 7 billion in value. business. He got a doctorate. in Neuroscience from Yale University, an MBA from the Yale School of Management, and a BA in Neuroscience from Columbia University.
Scipher Medicine’s strong test pipeline targets approved therapies with low patient response rates for multiple complex autoimmune diseases, enabling clinicians to make evidence-based treatment decisions and improve treatment outcomes while by saving payers on unnecessary spending on ineffective drugs, representing a market opportunity of $ 42 billion.
About Scipher Medicine®
Scipher Medicine, a precision immunology company, believes patients deserve straightforward answers to treatment options based on scientifically supported data. Take advantage of our exclusive Spectra® platform and artificial intelligence, we market liquid-based tests revealing the unique molecular signature of a person’s disease and combine that signature with the most effective therapy, ensuring optimal treatment from day one. The unprecedented amount of molecular patient data generated from patients tested further stimulates the discovery and development of new and more effective therapies. We partner with payers, suppliers and pharmaceutical companies across the healthcare value chain to bring precision medicine to autoimmune diseases. Visit www.sciphermedicine.com and follow Scipher on Twitter, Facebook and LinkedIn.